Immunogen, Inc. (IMGN) Tops Q3 EPS by 13c; Sees Wider FY13 Loss
Get Alerts IMGN Hot Sheet
Price: $31.25 --0%
EPS Growth %: +100.0%
Financial Fact:
Other (expense) income, net: 129K
Today's EPS Names:
BFRI, HCTI, IMPM, More
EPS Growth %: +100.0%
Financial Fact:
Other (expense) income, net: 129K
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
Immunogen, Inc. (NASDAQ: IMGN) reported Q3 EPS of ($0.02), $0.13 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $25 million versus the consensus estimate of $11.94 million.
ImmunoGen now expects its net loss for its fiscal year ending June 30, 2013 to be between $76 million to $80 million, its net cash used in operations to be between $65 million to $69 million, and its capital expenditures to be between $4 million to $5 million. Cash and cash equivalents at June 30, 2013 are anticipated to be between $186 million to $190 million.
This compares with previous guidance, issued in January 2013, of a projected net loss between $70 million to $74 million, net cash used in operations of between $78 million to $82 million, comparable capital expenditures, and ending the fiscal year on June 30, 2013 with cash and cash equivalents between $172 million to $176 million.
For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.
ImmunoGen now expects its net loss for its fiscal year ending June 30, 2013 to be between $76 million to $80 million, its net cash used in operations to be between $65 million to $69 million, and its capital expenditures to be between $4 million to $5 million. Cash and cash equivalents at June 30, 2013 are anticipated to be between $186 million to $190 million.
This compares with previous guidance, issued in January 2013, of a projected net loss between $70 million to $74 million, net cash used in operations of between $78 million to $82 million, comparable capital expenditures, and ending the fiscal year on June 30, 2013 with cash and cash equivalents between $172 million to $176 million.
For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Singular Genomics Systems, Inc. (OMIC) Reports In-Line Q4 EPS
- Adverum Biotechnologies (ADVM) Tops Q4 EPS by 11c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!